Clinical Trials Browser

Congenital Abnormalities, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2 Terminated

14 enrolled 9 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00871689 2017-12-28

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Phase 2 Terminated

2 enrolled 13 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

Phase 2 Terminated

21 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT02111863 2017-09-19

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Terminated

6 enrolled 9 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00089778 2017-08-01

Vaccine Treatment of Kidney Cancer

Phase 2 Terminated

11 enrolled 12 charts

Genitourinary

Kidney Neoplasms

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT02259348 2017-05-30

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Phase 2 Terminated

12 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01754376 2017-04-12

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Phase 2 Terminated

6 enrolled 12 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00610311 2015-10-28

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

3 enrolled 10 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00612222 2015-10-28

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

4 enrolled 9 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00704938 2015-10-28

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Phase 2 Terminated

3 enrolled 8 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2 Terminated

50 enrolled 13 charts

Dermatologic

Melanoma

NCT01160445 2015-10-28

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Phase 2 Terminated

9 enrolled 9 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT01495572 2015-10-15

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Phase 2 Terminated

5 enrolled 9 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00006113 2014-05-22

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Terminated

25 enrolled

Dermatologic

Melanoma

NCT00941928 2014-05-22

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase 2 Terminated

2 enrolled 3 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase 2 Terminated

58 enrolled

Dermatologic

Melanoma

NCT00509496 2013-01-15

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase 2 Terminated

21 enrolled 11 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT00005788 2012-06-06

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Phase 2 Terminated

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00138229 2012-03-29

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Phase 2 Terminated

6 enrolled

Dermatologic

Melanoma

NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Phase 2 Terminated

12 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00250861 2008-04-21

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Phase 2 Terminated

110 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

NB2013-HR

Biochemotherapy With Temozolomide for Metastatic Melanoma

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

p53 Vaccine for Ovarian Cancer

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Vaccine Treatment of Kidney Cancer

Drosophila-generated CTL

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma